Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4347859 in healthy volunteers
NCT06188507Phase 1Suspended
- Sponsor
- GSK
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gsk4347859 in systemic lupus erythematosus (SLE) (5 cohorts), sponsored by GSK. Primary endpoints: Adverse Events at 30 days, Serious Adverse Events at 30 days and 6 more. Started Jan 2024; status: suspended.
02
Drugs
gsk4347859
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06188507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188507.